Author of

• 10801

  +

  P1.11 - Poster Session 1 - NSCLC Novel Therapies (ID 208)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10813

    +

    P1.11-012 - Clinical observation from the treatment of icotinib for 196 cases with advanced non-small cell lung cancer (ID 1084)

    09:30 - 09:30  |  Author(s): L.C. Shi
    • Abstract

    Background
    Icotinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a large number of previous studies have demonstrated that icotinib is a safe and efficacious molecule-targeted drug. The treatment of icotinib improves the quality of life and prolongs the survival time for patients with advanced non-small cell lung cancer (NSCLC) who suffer the failure of platinum-based chemotherapy. The aim of this study is to evaluate the efficacy and safety of the treatment of icotinib on patients with advanced NSCLC.

    Methods
    From August 2011 to March 2013, 196 patients with advanced NSCLC were enrolled for treatment with icotinib including 104 male and 92 female. The age of the patients ranged from 39 to 85 years old, with a median age of 65 years old. There were 66 smokers and 130 never-smokers. By the cytological or histological analysis, all cases were validated as NSCLC which included 159 cases of adenocarcinoma, 22 cases of squamous carcinoma, and 15 cases of other carcinoma. According to the Union for International Cancer Control lung cancer staging system (1997 version), 9 patients were at stage IIIB and 187 patients were at stage IV. Among them, 151 patients had been given one or more chemotherapy regimens, and 45 had not been given any chemotherapy because they were intolerant of or reluctant about chemotherapy. A total of 196 patients received the treatment of icotinib at a dose of 125 mg, 3 times per day. The treatment of icotinib was carried out until the observation of disease progression or the development of unacceptable toxicity.

    Results
    After the treatment of icotinib for the total of 196 patients with advanced NSCLC，two (1.0%) patients achieved complete remission (CR), 58 (29.6%) patients achieved partial response (PR), 78 (39.8%) patients achieved stable disease (SD), and 58 (29.6%) patients exhibited progression of disease (PD). the overall response rate (ORR) and the disease controlled rate (DCR) of icotinib was 30.6％(60/196) and 70.4％(138/196), respectively. The ORR and DCR were significantly improved in patients with adenocarcinoma compared with those with non-adenocarcinoma (P < 0.05).The median progression-free survival was 5.0 months. Icotinib had a moderate effect for the treatment of brain metastasis of lung cancer. Among 21 patients with brain metastasis, 8 patients achieved PR and 8 achieved SD. The main toxicities were showed to be rash (31.6%, 62/196) and diarrhea of grade I to II (16.3%, 32/196). No bone marrow suppression and impaired renal function were observed.

    Conclusion
    Icotinib showed a definite efficacy with little toxicity for patients with advanced NSCLC. The treatment of icotinib effectively relieved the symptoms and improved the life quality for patients. Also, patients were well tolerant of the treatment of icotinib. As an EGFR-targeted agent, icotinib represents a new safe and efficacious therapeutic option for patients with tumor relapse or metastasis who are intolerant of or reluctant about chemotherapy.